Selection of data sets for FAIRification in drug discovery and development: Which, why, and how?

Cost-Benefit Analysis Drug Discovery
Cost–benefit Drug discovery FAIR FAIRification Pharmaceutical R&D

Journal

Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391

Informations de publication

Date de publication:
08 2022
Historique:
received: 14 01 2022
revised: 28 04 2022
accepted: 10 05 2022
pubmed: 21 5 2022
medline: 22 6 2022
entrez: 20 5 2022
Statut: ppublish

Résumé

Despite the intuitive value of adopting the Findable, Accessible, Interoperable, and Reusable (FAIR) principles in both academic and industrial sectors, challenges exist in resourcing, balancing long- versus short-term priorities, and achieving technical implementation. This situation is exacerbated by the unclear mechanisms by which costs and benefits can be assessed when decisions on FAIR are made. Scientific and research and development (R&D) leadership need reliable evidence of the potential benefits and information on effective implementation mechanisms and remediating strategies. In this article, we describe procedures for cost-benefit evaluation, and identify best-practice approaches to support the decision-making process involved in FAIR implementation.

Identifiants

DOI: 10.1016/j.drudis.2022.05.010 PMID: 35595012 PMC: PMC9236643
pubmed: 35595012
pii: S1359-6446(22)00199-4
doi: 10.1016/j.drudis.2022.05.010
pmc: PMC9236643
pii:
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2080-2085

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

Drug Discov Today. 2021 Mar;26(3):626-630
pubmed: 33338655
Eur J Hum Genet. 2019 Aug;27(8):1159-1167
pubmed: 30996335
Nat Rev Drug Discov. 2019 Jun;18(6):463-477
pubmed: 30976107
PLoS Comput Biol. 2018 Mar 15;14(3):e1005873
pubmed: 29543799
Nature. 2018 May;557(7707):S55-S57
pubmed: 29849160
Patterns (N Y). 2021 Sep 10;2(9):100322
pubmed: 34553169
Sci Data. 2020 Jun 19;7(1):188
pubmed: 32561801
Sci Data. 2016 Mar 15;3:160018
pubmed: 26978244
Eur J Hum Genet. 2018 Jul;26(7):931-936
pubmed: 29777206
Eur J Hum Genet. 2020 Jun;28(6):724-727
pubmed: 32376989
Drug Discov Today. 2021 May;26(5):1107-1110
pubmed: 33493454
Biopreserv Biobank. 2018 Apr;16(2):97-105
pubmed: 29359962
Drug Discov Today. 2019 Apr;24(4):933-938
pubmed: 30690198
Drug Discov Today. 2018 Apr;23(4):788-801
pubmed: 29337204
ALTEX. 2021 Feb 25;38(2):187-197
pubmed: 33637997
Comput Struct Biotechnol J. 2013 Nov 27;6:e201303017
pubmed: 24688725

Auteurs

Ebtisam Alharbi (E)

Department of Computer Science, The University of Manchester, Oxford Road, Manchester, UK; College of Computer and Information Systems, Umm Al-Qura University, Mecca, Saudi Arabia.

Yojana Gadiya (Y)

Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Schnackenburgallee 114, 22525 Hamburg, and Theodor Stern Kai 7, 60590 Frankfurt, Germany; Fraunhofer Cluster of Excellence for Immune Mediated Diseases (CIMD), Theodor Stern Kai 7, 60590 Frankfurt, Germany.

David Henderson (D)

Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13353 Berlin, Germany.

Andrea Zaliani (A)

Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Schnackenburgallee 114, 22525 Hamburg, and Theodor Stern Kai 7, 60590 Frankfurt, Germany; Fraunhofer Cluster of Excellence for Immune Mediated Diseases (CIMD), Theodor Stern Kai 7, 60590 Frankfurt, Germany.

Alejandra Delfin-Rossaro (A)

CERPOP, UMR 1295, INSERM, Université Paul Sabatier -Toulouse III, France.

Anne Cambon-Thomsen (A)

CERPOP, UMR 1295, INSERM, Université Paul Sabatier -Toulouse III, France.

Manfred Kohler (M)

Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Schnackenburgallee 114, 22525 Hamburg, and Theodor Stern Kai 7, 60590 Frankfurt, Germany; Fraunhofer Cluster of Excellence for Immune Mediated Diseases (CIMD), Theodor Stern Kai 7, 60590 Frankfurt, Germany.

Gesa Witt (G)

Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Schnackenburgallee 114, 22525 Hamburg, and Theodor Stern Kai 7, 60590 Frankfurt, Germany; Fraunhofer Cluster of Excellence for Immune Mediated Diseases (CIMD), Theodor Stern Kai 7, 60590 Frankfurt, Germany.

Danielle Welter (D)

Luxembourg Centre for Systems Biomedicine, ELIXIR Luxembourg, University of Luxembourg, L-4367 Belval, Luxembourg.

Nick Juty (N)

Department of Computer Science, The University of Manchester, Oxford Road, Manchester, UK.

Caroline Jay (C)

Department of Computer Science, The University of Manchester, Oxford Road, Manchester, UK.

Ola Engkvist (O)

Discovery Sciences, R&D, AstraZeneca, SE-43183 Mölndal, Sweden.

Carole Goble (C)

Department of Computer Science, The University of Manchester, Oxford Road, Manchester, UK.

Dorothy S Reilly (DS)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Venkata Satagopam (V)

Luxembourg Centre for Systems Biomedicine, ELIXIR Luxembourg, University of Luxembourg, L-4367 Belval, Luxembourg.

Vassilios Ioannidis (V)

SIB Swiss Institute of Bioinformatics, Quartier Sorge - Batiment Amphipole, 1015 Lausanne, Switzerland. Electronic address: Vassilios.Ioannidis@sib.swiss.

Wei Gu (W)

Luxembourg Centre for Systems Biomedicine, ELIXIR Luxembourg, University of Luxembourg, L-4367 Belval, Luxembourg. Electronic address: Wei.Gu@uni.lu.

Philip Gribbon (P)

Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Schnackenburgallee 114, 22525 Hamburg, and Theodor Stern Kai 7, 60590 Frankfurt, Germany; Fraunhofer Cluster of Excellence for Immune Mediated Diseases (CIMD), Theodor Stern Kai 7, 60590 Frankfurt, Germany. Electronic address: Philip.Gribbon@itmp.fraunhofer.de.

Articles similaires

A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery.

Philip R Coryell, Paul B Hardy, Susan Chubinskaya et al.
1.00
Humans Chondrocytes Osteoarthritis Matrix Metalloproteinase 13 Drug Discovery

A propensity score-matched cost-effectiveness analysis of magnetic resonance-guided laser interstitial thermal therapy versus craniotomy for brain tumor radiation necrosis.

Jia-Shu Chen, Alexander F Haddad, Jason E Chung et al.
1.00
Humans Cost-Benefit Analysis Brain Neoplasms Male Female

Cost-effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-COVID-19 condition after hospitalisation for COVID-19: the REGAIN RCT.

Henry Nwankwo, James Mason, Martin Underwood et al.
1.00
Humans COVID-19 Cost-Benefit Analysis Male United Kingdom

Cost and cost-effectiveness of digital technologies for support of tuberculosis treatment adherence: a systematic review.

Cedric Kafie, Mona Salaheldin Mohamed, Miranda Zary et al.
1.00
Humans Cost-Benefit Analysis Tuberculosis Medication Adherence Digital Technology

Classifications MeSH

questionsmedicales.fr › Organisations et économie des soins de santé › Économie › Coûts et analyse des coûts › Analyse coût-bénéfice › Selection of data sets for FAIRification in...
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Découverte de médicament › Selection of data sets for FAIRification in...